MagForce Nanotechnologies Completes Patient Recruitment For Pivotal Glioblastoma Study

MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy.